Jane Street
FULC icon

Jane Street’s Fulcrum Therapeutics FULC Stock Holding History

Jane Street’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$163K Sell
21,300
-15,400
-42% -$143K ﹤0.01% 10319
2025
Q4 		$415K Buy
+36,700
New +$373K ﹤0.01% 8117
2024
Q4 		– Sell
-70,200
Closed -$251K – 9815
2024
Q3 		$251K Buy
+70,200
New +$521K ﹤0.01% 8317
2022
Q1 		– Sell
-13,400
Closed -$237K – 10530
2021
Q4 		$237K Sell
13,400
-26,900
-67% -$533K ﹤0.01% 8562
2021
Q3 		$1.14M Buy
+40,300
New +$764K ﹤0.01% 5654

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Jane Street's FULC Position: Q1 2026 in Review

Jane Street reduced its Fulcrum Therapeutics (FULC) stake by 37% in Q1 2026, selling an estimated $1.7M and leaving 310,417 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4750.

Jane Street first reported a position in FULC in Q3 2021 and has held it in 18 quarters since. The position peaked at $5.58M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Jane Street held 310,417 shares of Fulcrum Therapeutics worth $2.38M as of Q1 2026.
  • Jane Street sold 183,333 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.7M.
  • Fulcrum Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #4750 holding.
  • Jane Street first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • Jane Street's Fulcrum Therapeutics position peaked at $5.58M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.